Good morning allIt looks like the City of Hope team just did a...

  1. 2,930 Posts.
    lightbulb Created with Sketch. 12949
    Good morning all

    It looks like the City of Hope team just did a conference presentation on the Check-acc trial (CF33 in Triple Neg Breast Cancer).

    The Abstract is here:

    https://aacrjournals.org/cancerimmunolres/article/13/2_Supplement/A105/751449

    Results - as expected. Only 9 subjects, and because it was at the very start of testing of CF33 they were bound b y the FDA's extremely cautious dosage limitation.. The highest they went was 106 - which is a tiny dose. Even so - most patients showed the expected immune response.

    The conclusions:

    CF33-hNIS-anti-PD-L1 induces tumor inflammation and immune activation as marked by increased tumor infiltration of CD4+ and CD8+ T cells, increased PD-L1 expression, and increased PD-1-positive T cells. Combination trials with CF33-hNIS and immune checkpoint inhibitor for the treatment of advanced solid tumors are ongoing. Additionally, more studies are needed to evaluate the use of OV in patients with high-risk stage II-III breast cancers.


    Interesting, but we still need to wait for further data from the MAST trial.

    Cheers

    Dave
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
26.5¢
Change
-0.015(5.36%)
Mkt cap ! $76.45M
Open High Low Value Volume
28.0¢ 28.0¢ 26.5¢ $376.3K 1.390M

Buyers (Bids)

No. Vol. Price($)
40 635301 26.5¢
 

Sellers (Offers)

Price($) Vol. No.
27.0¢ 114803 10
View Market Depth
Last trade - 14.34pm 31/07/2025 (20 minute delay) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.